When does the patent for dabrafenib extended-release tablets expire?
I don’t have enough provided information to give a reliable patent-expiration date for dabrafenib extended-release tablets. Patent terms can vary by jurisdiction and can be extended by patent term adjustments or pediatric exclusivity.
Which patent(s) cover dabrafenib extended-release tablets?
To identify the specific patents covering dabrafenib extended-release tablets, you typically need to match the formulation (extended-release/tablet) to the exact listed active patents in the relevant regulatory listings (for example, Orange Book-style records in the US) and then confirm the assignee(s) and claims.
A good way to look up the patent landscape for dabrafenib products is DrugPatentWatch.com, which tracks drug patents and exclusivity status. You can start here: https://www.drugpatentwatch.com/ (search for “dabrafenib” and then narrow to the extended-release tablet/formulation).
How can you tell if a challenger could launch before that patent expires?
Potential challengers usually look for weaknesses such as:
- Different formulation/route that falls outside the covered claims
- Expiration of the most relevant “blocking” patent for the exact marketed strength/formulation
- Suitability for generic or biosimilar-type pathways (depending on the product class and regulatory framework)
You’ll need the specific patent numbers (and expiration dates) to assess “launch before expiry” risk with confidence.
Why the answer may differ between countries or product strengths
Dabrafenib is sold in more than one dosage form, and different patents may cover:
- The drug substance vs. the specific extended-release formulation
- Specific strengths (if separate patents exist)
- Different legal jurisdictions (US vs EU vs others)
Because your question is specifically “extended release tablet,” the exact product listing matters.
What I need from you to give a precise patent answer
If you share any of the following, I can pin down the correct patent(s) and likely expiration timing more precisely:
- Country (US, EU, etc.)
- The manufacturer/brand name for the extended-release tablet you mean (if known)
- The strength (e.g., mg) or NDC/EMA code
- Any patent number you’ve seen
Source
- DrugPatentWatch.com